“Eric is one of the most astute, experienced advisors that I know, and his joining the Advisory Board is a welcome addition as we bring the Reveal product to market and expand the Company
MOUNTAIN VIEW, Calif. (PRWEB) September 09, 2019
Specific Diagnostics is very pleased to announce that Eric B. Stang has joined Specific’s Advisory Board. Mr. Stang is an experienced public company CEO and Board Member, currently CEO and Chairman of OOMA (NYSE), as well as member of the Board of Directors of Rambus (NASDAQ). In a diverse career that spans regulated medical technologies as well as semiconductors, Mr. Stang was most recently director of InvenSense, Inc., a publicly traded MEMS semiconductor company, and Solta Medical, Inc., a publicly traded medical aesthetics company. Mr. Stang holds an A.B. in Economics from Stanford University and an M.B.A from Harvard Business School. He brings Specific the benefits of his experience in growing commercial organizations and in the development of regulated medical products, as well as deep practical experience in the management of both public and private growth companies.
“I am gratified to rejoin Specific, where I had been an early advisor, to help now that its first important products are being readied for market, in Europe and the United States. I have known the management team for years and am not surprised that they have recently attracted private equity investment from a firm as experienced and distinguished as Telegraph Hill Partners, along with the substantial governmental support they have had. Given the worldwide importance of new means to address antibiotic resistant infection, and the simplicity and elegance of Specific’s enabling technology, I believe we have the right solutions for a big problem, coming to market at the right time. It will be my pleasure to work with Specific’s leadership to help guide their pursuit of these opportunities in any way I can,” said Mr. Stang.
“Eric is one of the most astute, experienced advisors that I know, and his joining the Advisory Board is a welcome addition as we bring the Reveal product to market and expand the Company,” said Paul A. Rhodes, Ph.D., CEO of Specific. “He combines operating, finance, and governance expertise, with CEO and Board Chairman roles in public and private companies ranging from Lexar Media, which had revenues of $800M before its sale, to makers of regulated medical products. It is our good fortune to have him available to assist Specific at time and I look forward to working with him.”
About Specific Diagnostics
Specific has developed in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture. The company’s unique patented technology leverages a low-cost printed chemical sensor array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. During growth in culture, bacteria emit organism-specific small molecule metabolite mixtures. Specific’s products utilize inexpensive printed sensor arrays to detect growth and quantify antibiotic efficacy with simple, automated, low-cost instruments and disposables. Accuracies of minimum inhibitory concentration (MIC) determination meet those of gold standard broth microdilution methods, but with results obtained fast enough to enable same-shift impact, directly from a diluted positive blood culture sample. The system will streamline lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific Diagnostics is located in two buildings in Mountain View, CA, with an office in Cambridge, UK. For more information, please visit http://www.specificdx.com.